A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation.

Trial Profile

A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2012

At a glance

  • Drugs Visilizumab (Primary) ; Hydrocortisone; Methylprednisolone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Sponsors Abbott Biotherapeutics Corp
  • Most Recent Events

    • 12 Mar 2012 Company (Facet Biotech Corporation) added as trial sponsor as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
    • 22 Dec 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top